Malaria Therapeutic Efficacy Study (TES) Kenya

PHASE4CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

December 18, 2022

Study Completion Date

December 18, 2022

Conditions
Uncomplicated Malaria
Interventions
DRUG

artemether lumefantrine

The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.

DRUG

dihydroartemisinin piperaquine

Antimalarial Combinations

Trial Locations (2)

Unknown

Makhonge Health Centre, Bungoma

Kaluo Health Centre, Siaya

All Listed Sponsors
collaborator

Kenya Ministry of Health

OTHER_GOV

collaborator

Centers for Disease Control and Prevention

FED

collaborator

United States Agency for International Development (USAID)

FED

lead

Jhpiego

OTHER

NCT04767191 - Malaria Therapeutic Efficacy Study (TES) Kenya | Biotech Hunter | Biotech Hunter